alexa

GET THE APP

Boceprevir in Mexico: Experience in a Series of Cases | OMICS International | Abstract
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Boceprevir in Mexico: Experience in a Series of Cases

José Antonio Mata-Marín*, Jorge Luis Sandoval-Ramirez, Bulmaro Manjarrez-Tellez, Jesus Enrique Gaytán-Martínez and Alberto Chaparro-Sánchez

Departamento de Infectología adultos. Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México

*Corresponding Author:
Jose Antonio Mata Marín
MD., Servicio de Infectología adultos
Hospital de Infectología Centro Médico
Nacional La Raza, Jacarandas esquina
con Seris s/n colonia la raza, México
Tel: + 52-57245900
Fax: 23924
E-mail: [email protected]

Received date: July 10, 2015 Accepted date: August 01, 2015 Published date: August 7, 2015

Citation:Mata-Marín JA, Sandoval-Ramirez JL, Manjarrez-Tellez B, Gaytán-Martínez JE, Chaparro-Sánchez A (2015) Boceprevir in Mexico: Experience in a Series of Cases. J Gastrointest Dig Syst 5: 317. doi:10.4172/2161-069X.1000317

Copyright: © 2015 Marin JAM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.

Abstract

There are many new drugs for HCV treatment. First generation protease inhibitors are about to be discontinued. However in developing countries the likelihood of access to these new drugs is vague. As in other poor countries, in Mexico we only have peg interferon and ribavirin for HCV treatment and the costs of the new therapies are hard to fill. This is a report of the outcome in 30 patients who received triple therapy adding Boceprevir to peg interferon and Ribavirin as part of an extended-access program. As described elsewhere Latinos have lower response rates. This is the largest series of cases in Mexico City, and we would like to share this experience with other developing countries.

Keywords

Google scholar citation report
Citations : 1337

Journal of Gastrointestinal & Digestive System received 1337 citations as per google scholar report

Journal of Gastrointestinal & Digestive System peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page
Top